OBIO Stock Analysis: Buy, Sell, or Hold?
OBIO - Orchestra BioMed Holdings, Inc. Ordinary Shares
$6.12
0.31 (5.34%)
▲
5d:
+29.11%
30d:
+38.46%
90d:
+50.37%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When OBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OBIO is 12.5% above its trading range ($5.44). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OBIO is 12.5% above its trading range ($5.44). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OBIO is currently trading at $6.12, which is considered extended relative to its 30-day fair value range of $4.40 to $5.44.
Technical Outlook: Technically, OBIO is in a uptrend. The price is approaching resistance at $6.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: OBIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.33 (+101.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OBIO is in a uptrend. The price is approaching resistance at $6.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: OBIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.33 (+101.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.40 -
$5.44
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+12.5% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 101.5% below Wall St target ($12.33)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.40 -
$5.44
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.71
Resistance Level
$6.25
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.04
Wall Street Target
$12.33
(+101.5%)
Revenue Growth (YoY)
-89.5%
Profit Margin
-184.6%
Share & Embed Analysis
Last updated: September 13, 2026 12:11 AM ET
Data refreshes hourly during market hours. Next update: 1:11 AM
Data refreshes hourly during market hours. Next update: 1:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
